Codexis

Codexis, Inc.
Company type
Public
Nasdaq: CDXS
Russell 2000 Component
IndustryProtein engineering, biocatalysis, industrial enzymes, fine chemicals
Founded2002; 24 years ago (2002)
HeadquartersRedwood City, California, U.S.
Key people
RevenueIncrease US$68.5 million (FY 2019)
Number of employees
165 (as of April 2020)[1]
Websitecodexis.com

Codexis, Inc. is a protein engineering company that develops enzymes for pharmaceutical, food and medical applications.[2][3]

History

Codexis is based in Redwood City, CA and was incorporated in 2002. It went public in April 2010 on NASDAQ,[4] and in October, acquired Maxygen's MolecularBreeding technology portfolio.[5]

Pharmaceutical

Codexis won the Presidential Green Chemistry Challenge Award from the U.S. Environmental Protection Agency (EPA) in 2006 for its work on a building block of Lipitor.[6] It then won a second time in 2010 for its work with Merck & Co. on the active ingredient in Januvia.[7]

Nutrition

In 2017, the company entered a partnership with Tate & Lyle to provide research and development for the production of new ingredients.[8] That same year, Codexis announced a collaboration with Nestle to provide enzymes for metabolic disorders.[9]

Biotherapeutics

In 2017, Codexis developed a recombinant phenylalanine ammonia-lyase (PAL) enzyme, to act as a substitute phenylalanine hydroxylase (PAH) enzyme for people who suffer from phenylketonuria.[3] The enzyme was in-licensed by Nestle Health Sciences.[3]

In 2020, Takeda Pharmaceutical announced a collaboration with Codexis to research and create gene therapies for rare diseases, including lysosomal storage disorders.[10]

Life science

In June 2020, they announced a partnership with Molecular Assemblies to engineer enzymes for DNA synthesis.[11]

Technology

Codexis uses directed evolution to develop its enzymes.[12][13] Using this method, scientists genetically engineer genes, then screen the enzymes produced to see if it creates the properties needed for a specific reaction.[13][7] Their protein engineering platform, called CodeEvolver, uses machine learning and high-throughput experimentation to learn protein sequence changes and their impacts on protein function.[3][14]

References

  1. ^ "Codexis Overview". Retrieved 2011-04-03.
  2. ^ "Codexis, Molecular Assemblies Ink Enzyme Engineering Collaboration Agreement". GenomeWeb. 23 June 2020. Retrieved 2021-03-12.
  3. ^ a b c d Hyde, Embriette (2019-09-04). "Engineering the future of biotherapeutics". SynBioBeta. Retrieved 2021-03-12.
  4. ^ Gelsi, Steve. "Codexis IPO blossoms on Earth Day". MarketWatch. Retrieved 10 June 2021.
  5. ^ "License Agreement - Maxygen, Inc". www.sec.gov.
  6. ^ "Codexis, Inc.:News Release".{{cite web}}: CS1 maint: deprecated archival service (link)
  7. ^ a b "Greener approach to Januvia cuts costs, ups yield". Reuters. 17 June 2010 – via www.reuters.com.
  8. ^ foodnavigator.com. "Tate & Lyle announce multiyear partnership with Codexis". foodnavigator.com. Retrieved 2021-05-27.
  9. ^ Mullin, Rick (2017-11-13). "BASF readies a medical food product". Chemical & Engineering News. Archived from the original on 2019-08-04. Retrieved 2021-05-27.
  10. ^ "Codexis and Takeda partner on gene therapies for rare diseases". www.pharmaceutical-technology.com. Retrieved 2021-06-18.
  11. ^ "Codexis, Molecular Assemblies Ink Enzyme Engineering Collaboration Agreement". Genomeweb. 2020-06-23. Retrieved 24 June 2021.
  12. ^ says, Jerry Jeff (2010-10-27). "Xconomy: Codexis Morphs From Big Science Project Into $100M Business". Xconomy. Retrieved 2021-05-24.
  13. ^ a b says, Jerry Jeff (2010-10-27). "Xconomy: Codexis Morphs From Big Science Project Into $100M Business". Xconomy. Retrieved 2021-06-02.
  14. ^ "Patenting Considerations for Artificial Intelligence in Biotech and Synthetic Biology". JD Supra.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.